Sustained operational strength leads to an upgrade
20/05/25 -"With 2025 having started on a strong note – on the back of a healthy performance across the segments - we have upgraded our earnings estimates for AstraZeneca. The margin improvement should continue ..."
Pages
70
Language
English
Published on
20/05/25
You may also be interested by these reports :
20/05/25
With 2025 having started on a strong note – on the back of a healthy performance across the segments – we have upgraded our earnings estimates for ...
19/05/25
Novo’s decision to oust its CEO came as a surprise, as the largest shareholder, the Novo Nordisk Foundation, decided to take action to prevent ...
19/05/25
Merck’s business model should not be that much impacted by the current global uncertainty but the depreciation of the USD has triggered, among other ...
15/05/25
Merck’s decision to provide detailed FY guidance was overshadowed by the significant impact of US President Trump’s actions. Consequently, ...